Pro Medicus share price jumps nearly 8% as ASX:PME steadies after post-results whiplash

Pro Medicus Ltd closed up 7.7% at A$125.96 on Tuesday, topping Australia’s S&P/ASX 200, which notched a 0.24% gain.

SYDNEY, Feb 17, 2026, 17:27 AEDT — The market has closed.

Pro Medicus Ltd closed up 7.7% at A$125.96 on Tuesday, topping Australia’s S&P/ASX 200, which notched a 0.24% gain.

The rebound stands out as traders keep wrestling with how to price “growth” when expensive software stocks keep taking a hit. With Lunar New Year thinning out activity across Asia and Wall Street dark for Presidents’ Day, local momentum and earnings are doing most of the work setting direction. Reuters

For Pro Medicus, it’s all about execution now—turning those big hospital deals from signatures into working, billable systems, and doing it fast.

Pro Medicus reported a 28.4% jump in revenue to A$124.8 million for the half-year ended Dec. 31, according to its Feb. 12 ASX filing. Underlying profit before tax climbed 29.7% to A$90.7 million. Net profit after tax surged to A$171.2 million, driven by A$149.1 million in unrealised gains from its 4D Medical stake—those gains haven’t been realised as cash. The company announced a fully franked interim dividend of 32 cents a share and said it continues to carry no debt.

Chief executive Sam Hupert noted the company’s biggest “go-live” happened late in the half, which meant “it had limited financial impact in the half but will have in the second half.” Hupert called Pro Medicus “a capital-light, software-only model,” pointing this out while AI-driven headlines sent software valuations swinging. Company Announcements

Pro Medicus develops imaging software for radiologists and clinicians—think storage, processing, and reading of medical scans. The RIS manages workflow, while the PACS acts as both library and viewer for images.

Revenue at the company tends to swing, since large deployments rarely land on schedule. If a rollout slips, usage fees and support sales get deferred to another quarter—contract or no contract.

Still, risks remain. A stumble in execution, and suddenly doubts about growth resurface. Investors, for their part, are quick to discount any one-off gains when sizing up real earnings strength.

Shares of Pro Medicus finished the session at A$125.96, bouncing around from A$116.98 up to A$127.55, per Intelligent Investor. Investors have their eyes on Feb. 26—the ex-dividend date for the interim 32-cent payout. That dividend lands on March 20.

Shan Ahmed Khan

Shan Ahmed Khan is a senior markets reporter at TS2.tech. His coverage ranges from stocks and technology to economic developments across global markets. He worked in investment research and market analysis before becoming a financial journalist and is a graduate of the Lahore University of Management Sciences (LUMS).

FMC stock price jumps nearly 7% as traders weigh strategic review and fresh Citi target cut
Previous Story

FMC stock price jumps nearly 7% as traders weigh strategic review and fresh Citi target cut

Bank of America Stock Price Today: BAC Rises as Fed Capital Relief Meets Credit Fears
Next Story

Bank of America Stock Price Today: BAC Rises as Fed Capital Relief Meets Credit Fears